 |
PDBsum entry 1m0e
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Transferase/DNA
|
PDB id
|
|
|
|
1m0e
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.1.1.37
- Dna (cytosine-5-)-methyltransferase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a 2'-deoxycytidine in DNA + S-adenosyl-L-methionine = a 5-methyl- 2'-deoxycytidine in DNA + S-adenosyl-L-homocysteine + H+
|
 |
 |
 |
 |
 |
2'-deoxycytidine in DNA
|
+
|
S-adenosyl-L-methionine
|
=
|
5-methyl- 2'-deoxycytidine in DNA
Bound ligand (Het Group name = )
corresponds exactly
|
+
|
S-adenosyl-L-homocysteine
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Mol Biol
321:591-599
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases.
|
|
L.Zhou,
X.Cheng,
B.A.Connolly,
M.J.Dickman,
P.J.Hurd,
D.P.Hornby.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Mechanism-based inhibitors of enzymes, which mimic reactive intermediates in the
reaction pathway, have been deployed extensively in the analysis of metabolic
pathways and as candidate drugs. The inhibition of cytosine-[C5]-specific DNA
methyltransferases (C5 MTases) by oligodeoxynucleotides containing
5-azadeoxycytidine (AzadC) and 5-fluorodeoxycytidine (FdC) provides a
well-documented example of mechanism-based inhibition of enzymes central to
nucleic acid metabolism. Here, we describe the interaction between the C5 MTase
from Haemophilus haemolyticus (M.HhaI) and an oligodeoxynucleotide duplex
containing 2-H pyrimidinone, an analogue often referred to as zebularine and
known to give rise to high-affinity complexes with MTases. X-ray crystallography
has demonstrated the formation of a covalent bond between M.HhaI and the 2-H
pyrimidinone-containing oligodeoxynucleotide. This observation enables a
comparison between the mechanisms of action of 2-H pyrimidinone with other
mechanism-based inhibitors such as FdC. This novel complex provides a molecular
explanation for the mechanism of action of the anti-cancer drug zebularine.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. The reaction pathway of C5 MTases in the presence
and in the absence of mechanism-based inhibitors. (a) The
reaction pathway for all C5 MTases involves the transfer of the
labile methyl group from S-adenosyl- Image -methionine (AdoMet)
to the 5 position of the cytosine ring, proceeds through a
covalent intermediate at position C6.[14] The nucleophilic
attack upon the C6 position of cytosine drives the subsequent
acquisition of the labile methyl group from AdoMet. (Note, the
protonation status of Glu119 in M.HhaI[36]). (b) The inhibition
by FdC. Following covalent complex formation and methyl
transfer, the analogue remains bound to the active-site Cys,
since abstraction of F cannot be achieved. (c) The inhibition by
AzaC. Following covalent complex formation at a C6 with enhanced
reactivity, slow methyl transfer may take place, but there is no
H at C5 to abstract and the covalent complex persists. (d) The
inhibition by zebularine. Following covalent complex formation
at a C6 with enhanced reactivity as with AzaC, facilitated
deamination at C4 cannot proceed, [33] since the amino moiety is
absent from the analogue. Note that the water molecule nearest
to the C4 atom is 3.6 Å away and the water molecule
nearest to the C5 atom is 3.3 Å away.
|
 |
Figure 2.
Figure 2. Structure of M.HhaI-AdoHcy-DNA containing
zebularine. (a) The structural impasse between the proposed
mechanism (outlined in Figure 1) and the barrier to substrate
access in duplex DNA was overcome elegantly by the phenomenon of
protein-induced base flipping. [15] Once the target base
(zebularine here) is released from the constraints of the
Watson-Crick base-pair, conventional active-site chemistry is
facilitated. (b) Zebularine difference electron density maps
(F[o] -F[c], a[c]) superimposed on the refined coordinates with
carbon atoms being yellow, oxygen atoms red, nitrogen atom blue,
and sulfur atom green, respectively. The blue electron density
map contoured at 5.0s was computed with the zebularine moiety
omitted from the atomic model. The green electron density maps
contoured above 5.5s were calculated with the C4, C5, and C6
atoms of zebularine omitted from the atomic model, respectively.
The zebularine is constrained in the plane of the ring by a
highly conserved network of hydrogen bonds (via E119 and R165)
and van der Waals interactions between the main-chain C=O group
of F79 and C4 and C5 atoms. (c) A view perpendicular to (b),
looking edge-on at the flipped zebularine molecule. A covalent
bond is observed between C6 of the zebularine ring and an
invariant thiolate side-chain C81, approaching the C6
perpendicular to the ring. The red electron density map
contoured above 10.0s was calculated with the sulfur atom of C81
omitted from the atomic model.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2002,
321,
591-599)
copyright 2002.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.S.Alva,
N.M.Hahn,
A.M.Aparicio,
R.Singal,
S.Yellapragada,
and
G.Sonpavde
(2011).
Hypomethylating agents for urologic cancers.
|
| |
Future Oncol,
7,
447-463.
|
 |
|
|
|
|
 |
J.Ren,
B.N.Singh,
Q.Huang,
Z.Li,
Y.Gao,
P.Mishra,
Y.L.Hwa,
J.Li,
S.C.Dowdy,
and
S.W.Jiang
(2011).
DNA hypermethylation as a chemotherapy target.
|
| |
Cell Signal,
23,
1082-1093.
|
 |
|
|
|
|
 |
T.Robak
(2011).
New nucleoside analogs for patients with hematological malignancies.
|
| |
Expert Opin Investig Drugs,
20,
343-359.
|
 |
|
|
|
|
 |
B.Betham,
S.Shalhout,
V.E.Marquez,
and
A.S.Bhagwat
(2010).
Use of Drosophila deoxynucleoside kinase to study mechanism of toxicity and mutagenicity of deoxycytidine analogs in Escherichia coli.
|
| |
DNA Repair (Amst),
9,
153-160.
|
 |
|
|
|
|
 |
C.Champion,
D.Guianvarc'h,
C.Sénamaud-Beaufort,
R.Z.Jurkowska,
A.Jeltsch,
L.Ponger,
P.B.Arimondo,
and
A.L.Guieysse-Peugeot
(2010).
Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine.
|
| |
PLoS One,
5,
e12388.
|
 |
|
|
|
|
 |
J.C.Chuang,
S.L.Warner,
D.Vollmer,
H.Vankayalapati,
S.Redkar,
D.J.Bearss,
X.Qiu,
C.B.Yoo,
and
P.A.Jones
(2010).
S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth.
|
| |
Mol Cancer Ther,
9,
1443-1450.
|
 |
|
|
|
|
 |
K.Sebova,
and
I.Fridrichova
(2010).
Epigenetic tools in potential anticancer therapy.
|
| |
Anticancer Drugs,
21,
565-577.
|
 |
|
|
|
|
 |
L.Maldonado,
and
M.O.Hoque
(2010).
Epigenomics and ovarian carcinoma.
|
| |
Biomark Med,
4,
543-570.
|
 |
|
|
|
|
 |
M.Pandey,
S.Shukla,
and
S.Gupta
(2010).
Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells.
|
| |
Int J Cancer,
126,
2520-2533.
|
 |
|
|
|
|
 |
N.A.Cherepanova,
A.L.Zhuze,
and
E.S.Gromova
(2010).
Inhibition of murine DNA methyltransferase Dnmt3a by DNA duplexes containing pyrimidine-2(1H)-one.
|
| |
Biochemistry (Mosc),
75,
1115-1125.
|
 |
|
|
|
|
 |
T.Baubec,
H.Q.Dinh,
A.Pecinka,
B.Rakic,
W.Rozhon,
B.Wohlrab,
A.von Haeseler,
and
O.Mittelsten Scheid
(2010).
Cooperation of multiple chromatin modifications can generate unanticipated stability of epigenetic States in Arabidopsis.
|
| |
Plant Cell,
22,
34-47.
|
 |
|
|
|
|
 |
Y.Iwase,
T.Shiraya,
and
K.Takeno
(2010).
Flowering and dwarfism induced by DNA demethylation in Pharbitis nil.
|
| |
Physiol Plant,
139,
118-127.
|
 |
|
|
|
|
 |
A.Pecinka,
M.Rosa,
A.Schikora,
M.Berlinger,
H.Hirt,
C.Luschnig,
and
O.Mittelsten Scheid
(2009).
Transgenerational stress memory is not a general response in Arabidopsis.
|
| |
PLoS ONE,
4,
e5202.
|
 |
|
|
|
|
 |
D.M.van Bemmel,
A.S.Brank,
R.Eritja,
V.E.Marquez,
and
J.K.Christman
(2009).
DNA (Cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic target site.
|
| |
Biochem Pharmacol,
78,
633-641.
|
 |
|
|
|
|
 |
G.Lal,
and
J.S.Bromberg
(2009).
Epigenetic mechanisms of regulation of Foxp3 expression.
|
| |
Blood,
114,
3727-3735.
|
 |
|
|
|
|
 |
M.Lemaire,
L.F.Momparler,
N.J.Raynal,
M.L.Bernstein,
and
R.L.Momparler
(2009).
Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.
|
| |
Cancer Chemother Pharmacol,
63,
411-416.
|
 |
|
|
|
|
 |
O.V.Kirsanova,
N.A.Cherepanova,
and
E.S.Gromova
(2009).
Inhibition of C5-cytosine-DNA-methyltransferases.
|
| |
Biochemistry (Mosc),
74,
1175-1186.
|
 |
|
|
|
|
 |
R.Thaler,
H.Karlic,
P.Rust,
and
A.G.Haslberger
(2009).
Epigenetic regulation of human buccal mucosa mitochondrial superoxide dismutase gene expression by diet.
|
| |
Br J Nutr,
101,
743-749.
|
 |
|
|
|
|
 |
S.Warncke,
A.Gégout,
and
T.Carell
(2009).
Phosphorothioation of oligonucleotides strongly influences the inhibition of bacterial (M.HhaI) and human (Dnmt1) DNA methyltransferases.
|
| |
Chembiochem,
10,
728-734.
|
 |
|
|
|
|
 |
T.Baubec,
A.Pecinka,
W.Rozhon,
and
O.Mittelsten Scheid
(2009).
Effective, homogeneous and transient interference with cytosine methylation in plant genomic DNA by zebularine.
|
| |
Plant J,
57,
542-554.
|
 |
|
|
|
|
 |
C.B.Yoo,
R.Valente,
C.Congiatu,
F.Gavazza,
A.Angel,
M.A.Siddiqui,
P.A.Jones,
C.McGuigan,
and
V.E.Marquez
(2008).
Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine.
|
| |
J Med Chem,
51,
7593-7601.
|
 |
|
|
|
|
 |
C.Ptak,
and
A.Petronis
(2008).
Epigenetics and complex disease: from etiology to new therapeutics.
|
| |
Annu Rev Pharmacol Toxicol,
48,
257-276.
|
 |
|
|
|
|
 |
S.S.Palii,
B.O.Van Emburgh,
U.T.Sankpal,
K.D.Brown,
and
K.D.Robertson
(2008).
DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
|
| |
Mol Cell Biol,
28,
752-771.
|
 |
|
|
|
|
 |
S.Veerla,
I.Panagopoulos,
Y.Jin,
D.Lindgren,
and
M.Höglund
(2008).
Promoter analysis of epigenetically controlled genes in bladder cancer.
|
| |
Genes Chromosomes Cancer,
47,
368-378.
|
 |
|
|
|
|
 |
D.J.Baker,
G.Wuenschell,
L.Xia,
J.Termini,
S.E.Bates,
A.D.Riggs,
and
T.R.O'Connor
(2007).
Nucleotide excision repair eliminates unique DNA-protein cross-links from mammalian cells.
|
| |
J Biol Chem,
282,
22592-22604.
|
 |
|
|
|
|
 |
E.M.Hurt,
S.B.Thomas,
B.Peng,
and
W.L.Farrar
(2007).
Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines.
|
| |
Br J Cancer,
97,
1116-1123.
|
 |
|
|
|
|
 |
L.Sigalotti,
E.Fratta,
S.Coral,
E.Cortini,
A.Covre,
H.J.Nicolay,
L.Anzalone,
L.Pezzani,
A.M.Di Giacomo,
E.Fonsatti,
F.Colizzi,
M.Altomonte,
L.Calabrò,
and
M.Maio
(2007).
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
|
| |
J Cell Physiol,
212,
330-344.
|
 |
|
|
|
|
 |
S.P.Rao,
M.P.Rechsteiner,
C.Berger,
J.A.Sigrist,
D.Nadal,
and
M.Bernasconi
(2007).
Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells.
|
| |
Mol Cancer,
6,
3.
|
 |
|
|
|
|
 |
T.E.Fandy,
H.Carraway,
and
S.D.Gore
(2007).
DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies.
|
| |
Cancer J,
13,
40-48.
|
 |
|
|
|
|
 |
C.B.Yoo,
and
P.A.Jones
(2006).
Epigenetic therapy of cancer: past, present and future.
|
| |
Nat Rev Drug Discov,
5,
37-50.
|
 |
|
|
|
|
 |
G.Le Gac,
P.O.Estève,
C.Ferec,
and
S.Pradhan
(2006).
DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1.
|
| |
J Biol Chem,
281,
24161-24170.
|
 |
|
|
|
|
 |
I.M.Adcock,
P.Ford,
P.J.Barnes,
and
K.Ito
(2006).
Epigenetics and airways disease.
|
| |
Respir Res,
7,
21.
|
 |
|
|
|
|
 |
Q.Lu,
X.Qiu,
N.Hu,
H.Wen,
Y.Su,
and
B.C.Richardson
(2006).
Epigenetics, disease, and therapeutic interventions.
|
| |
Ageing Res Rev,
5,
449-467.
|
 |
|
|
|
|
 |
F.Lyko,
and
R.Brown
(2005).
DNA methyltransferase inhibitors and the development of epigenetic cancer therapies.
|
| |
J Natl Cancer Inst,
97,
1498-1506.
|
 |
|
|
|
|
 |
J.C.Meier,
C.Henneberger,
I.Melnick,
C.Racca,
R.J.Harvey,
U.Heinemann,
V.Schmieden,
and
R.Grantyn
(2005).
RNA editing produces glycine receptor alpha3(P185L), resulting in high agonist potency.
|
| |
Nat Neurosci,
8,
736-744.
|
 |
|
|
|
|
 |
M.Biel,
V.Wascholowski,
and
A.Giannis
(2005).
Epigenetics--an epicenter of gene regulation: histones and histone-modifying enzymes.
|
| |
Angew Chem Int Ed Engl,
44,
3186-3216.
|
 |
|
|
|
|
 |
G.Egger,
G.Liang,
A.Aparicio,
and
P.A.Jones
(2004).
Epigenetics in human disease and prospects for epigenetic therapy.
|
| |
Nature,
429,
457-463.
|
 |
|
|
|
|
 |
J.C.Cheng,
C.B.Yoo,
D.J.Weisenberger,
J.Chuang,
C.Wozniak,
G.Liang,
V.E.Marquez,
S.Greer,
T.F.Orntoft,
T.Thykjaer,
and
P.A.Jones
(2004).
Preferential response of cancer cells to zebularine.
|
| |
Cancer Cell,
6,
151-158.
|
 |
|
|
|
|
 |
J.C.Cheng,
D.J.Weisenberger,
F.A.Gonzales,
G.Liang,
G.L.Xu,
Y.G.Hu,
V.E.Marquez,
and
P.A.Jones
(2004).
Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells.
|
| |
Mol Cell Biol,
24,
1270-1278.
|
 |
|
|
|
|
 |
O.M.Subach,
A.V.Khoroshaev,
D.N.Gerasimov,
V.B.Baskunov,
A.K.Shchyolkina,
and
E.S.Gromova
(2004).
2-Pyrimidinone as a probe for studying the EcoRII DNA methyltransferase-substrate interaction.
|
| |
Eur J Biochem,
271,
2391-2399.
|
 |
|
|
|
|
 |
R.Brown,
and
J.A.Plumb
(2004).
Demethylation of DNA by decitabine in cancer chemotherapy.
|
| |
Expert Rev Anticancer Ther,
4,
501-510.
|
 |
|
|
|
|
 |
J.C.Cheng,
C.B.Matsen,
F.A.Gonzales,
W.Ye,
S.Greer,
V.E.Marquez,
P.A.Jones,
and
E.U.Selker
(2003).
Inhibition of DNA methylation and reactivation of silenced genes by zebularine.
|
| |
J Natl Cancer Inst,
95,
399-409.
|
 |
|
|
|
|
 |
V.E.Marquez,
R.Eritja,
J.A.Kelley,
D.Vanbemmel,
and
J.K.Christman
(2003).
Potent inhibition of HhaI DNA methylase by the aglycon of 2-(1H)-pyrimidinone riboside (zebularine) at the GCGC recognition domain.
|
| |
Ann N Y Acad Sci,
1002,
154-164.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |